Bank of New York Mellon’s Sigilon Therapeutics, Inc. Common Stock SGTX Stock Holding History

Bank of New York Mellon’s Portfolio SGTX Stock Details SGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,413	Closed	-$66K	–	4742
2022 Q1	$66K	Sell	3,413 -557	-14%	-$12.4K	﹤0.01%	4483
2021 Q4	$142K	Buy	3,970 +927	+30%	+$52.8K	﹤0.01%	4349
2021 Q3	$223K	Buy	3,043 +962	+46%	+$74K	﹤0.01%	4166
2021 Q2	$290K	Buy	2,081 +752	+57%	+$132K	﹤0.01%	3978
2021 Q1	$386K	Buy	+1,329	New	+$528K	﹤0.01%	3821

Other funds holding SGTX

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of New York Mellon's SGTX Position: Q2 2022 in Review

Bank of New York Mellon sold out of Sigilon Therapeutics, Inc. Common Stock (SGTX) in Q2 2022, closing a stake of 3,413 shares — an estimated $66K sold.

Bank of New York Mellon first reported a position in SGTX in Q1 2021 and held it in 5 quarters. The position peaked at $386K in Q1 2021. 37 funds tracked by Wall St. Rank hold SGTX as of Q2 2022.

Bank of New York Mellon reported no remaining Sigilon Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Bank of New York Mellon sold 3,413 Sigilon Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $66K.
Bank of New York Mellon first reported a position in Sigilon Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
Bank of New York Mellon's Sigilon Therapeutics, Inc. Common Stock position peaked at $386K in Q1 2021.
37 funds tracked by Wall St. Rank held Sigilon Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Bank of New York Mellon's 13F filing for Q2 2022, filed 15 Aug 2022.